Abstract:The HIV-1 CA protein has gained remarkable attention as a promising therapeutic target for the development of new antivirals, due to its pivotal roles in HIV-1 replication (structural and regulatory). Herein, we report the design and synthesis of three series of benzenesulfonamide-containing phenylalanine derivatives obtained by further structural modifications of PF-74 to aid in the discovery of more potent and drug-like HIV-1 CA inhibitors. Structure-activity relationship studies of these compounds led to the identification of new phenylalanine derivatives with a piperazinone moiety, represented by compound 11l, which exhibited anti-HIV-1(NL4-3) activity 5.78-fold better than PF-74. Interestingly, 11l also showed anti-HIV-2(ROD) activity (EC50 = 31 nM), with almost 120 times increased potency over PF-74. However, due to the higher significance of HIV-1 as compared to HIV-2 for the human population, this manuscript focuses on the mechanism of action of our compounds in the context of HIV-1. SPR studies on representative compounds confirmed CA as the binding target. The action stage determination assay demonstrated that these inhibitors exhibited antiviral activities with a dual-stage inhibition profile. The early-stage inhibitory activity of compound 11l was 6.25 times more potent as compared to PF-74 but appeared to work via the accelerating capsid core assembly rather than stabilization. However, the mechanism by which they exert their antiviral activity in the late stage appears to be the same as PF-74 with less infectious HIV-1 virions produced in their presence, as judged p24 content studies. MD simulations provided the key rationale for the promising antiviral potency of 11l. Additionally, 11l exhibited a modest increase in HLM and human plasma metabolic stabilities as compared to PF-74, as well as a moderately improved pharmacokinetic profile, favorable oral bioavailability, and no acute toxicity. These studies provide insights and serve as a starting point for subsequent medicinal chemistry efforts in optimizing these promising HIV inhibitors.

Small organic molecules targeting PCAF bromodomain as potent inhibitors of HIV-1 replication

Selective Small Molecules Blocking HIV-1 Tat and Coactivator PCAF Association.

Fluorescence polarization for the evaluation of small-molecule inhibitors of PCAF BRD/Tat-AcK50 association.

Structure-guided optimization of small molecules inhibiting human immunodeficiency virus 1 Tat association with the human coactivator p300/CREB binding protein-associated factor.

Synthesis and biological acitivity of 3-aryloxy-1-propylamine derivatives as HIV-1 Tat/PCAF BRD inhibitor

Discovery of Phenylalanine Derivatives As Potent HIV-1 Capsid Inhibitors from Click Chemistry-Based Compound Library.

Discovery of Novel 1,4-Disubstituted 1,2,3-Triazole Phenylalanine Derivatives As HIV-1 Capsid Inhibitors

Design, Synthesis and Biological Evaluation of Substituted Guanidine Indole Derivatives As Potential Inhibitors of HIV-1 Tat-TAR Interaction.

From Design to Biological Mechanism Evaluation of Phenylalanine-Bearing HIV-1 Capsid Inhibitors Targeting a Vital Assembly Interface

Design, Synthesis, and Mechanism Study of Dimerized Phenylalanine Derivatives As Novel HIV-1 Capsid Inhibitors.

Design, Synthesis, and Mechanistic Study of 2-Pyridone-bearing Phenylalanine Derivatives As Novel HIV Capsid Modulators

Preliminary SAR and Biological Evaluation of Potent HIV-1 Protease Inhibitors with Pyrimidine Bases As Novel P2 Ligands to Enhance Activity Against DRV-resistant HIV-1 Variants

Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy.

Design, Synthesis and Structure—Activity Relationships of Phenylalanine-Containing Peptidomimetics As Novel HIV-1 Capsid Binders Based on Ugi Four-Component Reaction

Design, synthesis, and antiviral activity of phenylalanine derivatives as HIV-1 capsid inhibitors

Design, Synthesis, and Biological Evaluation of Highly Potent Small Molecule–Peptide Conjugates As New HIV-1 Fusion Inhibitors

Low-molecular-weight anti-HIV-1 agents targeting HIV-1 capsid proteins

Synthesis, Biological Evaluation and Molecular Docking Study of N-(2-methoxyphenyl)-6-((4-nitrophenyl)sulfonyl)benzamide Derivatives As Potent HIV-1 Vif Antagonists.

Synthesis and Biological Evaluation of Pyridinone Analogues As Novel Potent HIV-1 NNRTIs.

Development of benzimidazole derivatives to inhibit HIV-1 replication through protecting APOBEC3G protein.

Discovery of Novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-n-arylacetamides As Potent Hiv-1 Inhibitors Using A Structure-Based Bioisosterism Approach